Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices - such as rebate walls - would likely lead to legal action being taken against PBMs.
Subscribe to:
Post Comments (Atom)
< + > Revenue Cycle Management – Healthcare IT Today Podcast Episode 196
For the 196th episode of the Healthcare IT Today Podcast , we are talking about revenue cycle management! We kick this episode off by sharin...
No comments:
Post a Comment